Clinical Trial Update: A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating bempegaldesleukin (BEMPEG) in combination with nivolumab in pediatric and young adult patients with recurrent or treatment-resistan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Ewing Sarcoma
• High-grade Glioma
• Leukemia and Lymphoma
• Malignant Neoplasms
• Medulloblastoma
• Miscellaneous Brain Tumors
• Miscellaneous Solid Tumors
• Neuroblastoma
• Rhabdomyosarcoma

Drugs mentioned

• bempegaldesleukin (BEMPEG; NKTR-214) (bempegaldesleukin)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Ependymoma, Ewing Sarcoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-03-24